NCT02502266 2026-03-05
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
Clinical Trials
9 trialsNCT06161025 2026-01-12
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT06321068 2025-08-14
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Bio-Thera Solutions
Phase 2/3 Terminated
NCT05255653 2024-11-29
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT05489848 2022-08-05
Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation
Fudan University
Phase 2/3 Not yet recruiting
NCT01196741 2015-05-05
SaPPrOC
University College, London
Phase 2/3 Completed
NCT00003880 2015-04-16
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00075712 2013-08-12
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed